It is well-established that adverse reaction analyses based on the FAERS database have the following limitations: passive reporting systems, heterogeneous data quality, difficulty in eliminating confounding factors, and an inability to establish causality [Reference Zou, Li, Wang, Deng, Wang and Hua51, Reference Zhao, Long and Wang52]
As these medications become among the most widely prescribed in the world, the ability to tailor treatment based on genetic profile or to target specific clinical outcomes such as cardiovascular risk reduction could transform prescribing practices well beyond their current primary use in obesity and diabetes management Sources New 23andMe Research Institute Study Identifies Genetic Predictors for GLP-1 Weight Loss Efficacy and Side Effects 23andME April 8, 2026 Genetic variations linked to weight loss, side effects from GLP-1 drugs Reuters April 10, 2026
Three semaglutide products are currently FDA-approved: Ozempic injections and Rybelsus tablets are approved to help lower blood sugar levels in people over 18 with type 2 diabetes mellitus
2001, 281 (1): L31-38
